Data on safety and tolerability of telmisartan (T) and T ϩ hydrochlorothiazide (HCTZ) in comparison with placebo (P) was consolidated from clinical trials.
P-60 DIHYDROPIRIDINE CALCIUM CHANNEL BLOCKERS AND DEPENDENT EDEMA: A COMPARISON BETWEEN AMLODIPINE AND LERCANIDIPINE IN ESSENTIAL HYPERTENSIVE PATIENTS
Roberto Pedrinelli, Alessandra Menegato, Marco Nuti, Giulia Dell'Omo, Alberto Balbarini, Mario Mariani. Dipartimento Cardiotoracico, Università di Pisa, Pisa, Italy. Background: Dependent leg edema complicates treatment with amlodipine (AMLO) and other dihydropiridine (DHP) calcium channel blocker (CCB)s and frequently obliges to interrupt an otherwise highly effective therapeutic regimen. Among other possible explanations, DHP CCBs may alter the balance between pre-and post-capillary pressures by dilating preferentially precapillary arterioles of the cutaneous microcirculation, thus increasing capillary pressure and promoting fluid extravasation. In contrast, DHP CCBs such as lercanidipine (LERCA), which may relax both pre-and post-capillary vessels in in-vitro studies, may induce a lesser degree of dependent edema. However, this hypothesis has never been tested in man.
Methods: We compared the leg edema-forming potential of AMLO and LERCA according to a cross-over, sequence-randomized experimental design carried out in 22 never treated mild-moderate uncomplicated essential hypertensive (EH) males (age: 48Ϯ5 yrs). Drugs were administered at doses (AMLO: 10 vs LERCA: 20 mg o.d.) equipotent on the basis of published titration studies. Active treatment was given for 2 weeks preceded and followed by 2 week wash-outs to allow the recovery of study variables to baseline. Leg weight (LW) was used as a surrogate measure of dependent edema; the parameter was measured by water plethysmography (accuracy within 5 grams; variation coefficient: 0.8%) at both legs and the data were averaged. Systolic and diastolic blood pressure (BP, the mean of at least 10 determinations) was recorded by an automated oscillometric device.
Results: (meansϮSD): AMLO (from 147Ϯ8/94Ϯ12 to 137Ϯ14/ 83Ϯ9 mmHg, pϽ.002) and LERCA (from 145Ϯ18/92Ϯ12 to 137Ϯ9/ 83Ϯ8 mmHg, pϽ0.01) decreased BP to a similar extent. Both drugs increased LW (AMLO: from 3244Ϯ306 to 3324Ϯ293 grams, pϽ0.001; LERCA: from 3256Ϯ279 to 3293Ϯ258 grams, pϽ0.04), but the increase was greater during AMLO (80Ϯ91 vs 37Ϯ74 grams, pϽ0.03).
Conclusions: These data, consistent with pharmacological differences previously reported at the in-vitro microvascular level, show for the first time in man that, for a similar drop in BP, the edema-forming potential of AMLO and LERCA, two CCBs belonging to the same DHP class, is not equivalent. The purpose of the study was to compare the costs and outcomes of antihypertensive therapeutic treatments (amlodipine besylate 10mg, felodipine 10mg, nifedipine 60mg, amlodipine/benazepril 2.5mg/10mg) for managed care patients with moderate to severe hypertension who had previously failed initial drug therapy (beta blockers or diuretics per JNC-VI).
A decision analysis model was developed to simulate hypertension management for a hypothetical cohort of patients with moderate to severe hypertension in a Managed Care Organization (nϭ200,000). Patients were distributed evenly between the four therapies (nϭ50,000). The model follows patients over the course of one year during which time patients may experience adverse drug reactions and success or failure of blood pressure control. Efficacy and tolerability estimates were obtained from a published meta-analysis and literature. Medical management was based on results from a physician survey. Costs included in the model were drug acquisition, routine follow-up, management of blood pressure control failure and adverse events. Model parameters were varied to test the stability of the conclusions (e.g., efficacy and tolerability were varied above and below the baseline).
Approximately 93% of patients responded to second-line therapy with amlodipine/benazepril at the end of one year, compared with 92% in the felodipine arm, 91% in the amlodipine besylate arm and 88% in the nifedipine arm. The percentage of patients who remained on initial therapy and did not require treatment modification (e.g., increase in dose, addition of a concomitant medication or a medication switch) due to drug intolerability or lack of blood pressure control was higher in the amlodipine/benazepril arm. The cost of amlodipine/benazepril was lower than the total cost of care of the other treatments: $51,700,000 for amlodipine/ benazepril versus $60,900,000, $58,100,000 and $60,950,000 for nifedipine, felodipine and amlodipine besylate, respectively. Increasing efficacy by one standard deviation resulted in a greater percentage of patients achieving BP control at a lower cost of treatment for all regimens. Amlodipine/benazepril remained the most effective at a lower cost because patients required fewer treatment modifications. Decreasing the efficacy estimate resulted in a slightly greater percentage of amlodipine 54A AJH-April 2002-VOL. 15, NO. 4 , PART 2 POSTERS: Antihypertensive Drugs Downloaded from https://academic.oup.com/ajh/article-abstract/15/S3/54A/230962 by guest on 10 December 2018
